| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 63 | 2025 | 1410 | 7.650 |
Why?
|
| Insulin Resistance | 58 | 2025 | 698 | 7.590 |
Why?
|
| Blood Glucose | 40 | 2025 | 1121 | 3.560 |
Why?
|
| Insulin | 40 | 2025 | 1168 | 3.350 |
Why?
|
| Obesity | 35 | 2024 | 2394 | 3.000 |
Why?
|
| Overweight | 13 | 2024 | 383 | 2.540 |
Why?
|
| Pediatric Obesity | 12 | 2025 | 415 | 2.410 |
Why?
|
| Insulin-Secreting Cells | 18 | 2020 | 146 | 2.320 |
Why?
|
| Adiposity | 11 | 2025 | 207 | 2.290 |
Why?
|
| Prediabetic State | 10 | 2024 | 64 | 2.270 |
Why?
|
| Metformin | 15 | 2024 | 166 | 1.920 |
Why?
|
| Diabetes Mellitus, Type 1 | 13 | 2023 | 861 | 1.910 |
Why?
|
| Body Mass Index | 23 | 2024 | 1696 | 1.790 |
Why?
|
| Hypoglycemic Agents | 13 | 2024 | 482 | 1.710 |
Why?
|
| Adolescent | 96 | 2025 | 20535 | 1.710 |
Why?
|
| Glucose Tolerance Test | 20 | 2025 | 206 | 1.560 |
Why?
|
| Body Composition | 16 | 2025 | 550 | 1.420 |
Why?
|
| Cardiorespiratory Fitness | 2 | 2022 | 11 | 1.280 |
Why?
|
| Adipose Tissue | 13 | 2021 | 504 | 1.270 |
Why?
|
| Glucose Intolerance | 9 | 2025 | 85 | 1.110 |
Why?
|
| Basal Metabolism | 2 | 2024 | 93 | 1.050 |
Why?
|
| Vascular Stiffness | 5 | 2022 | 81 | 1.030 |
Why?
|
| Glucose | 7 | 2023 | 870 | 1.000 |
Why?
|
| Child | 69 | 2025 | 25761 | 0.980 |
Why?
|
| Metabolic Syndrome | 7 | 2021 | 364 | 0.980 |
Why?
|
| Glucose Clamp Technique | 18 | 2021 | 75 | 0.970 |
Why?
|
| Endothelium, Vascular | 3 | 2019 | 487 | 0.930 |
Why?
|
| Hyperglycemia | 4 | 2023 | 235 | 0.910 |
Why?
|
| Calorimetry | 1 | 2024 | 63 | 0.900 |
Why?
|
| C-Peptide | 9 | 2021 | 109 | 0.830 |
Why?
|
| Male | 86 | 2025 | 64870 | 0.830 |
Why?
|
| Female | 89 | 2025 | 70584 | 0.830 |
Why?
|
| Humans | 113 | 2025 | 131924 | 0.810 |
Why?
|
| Obesity, Abdominal | 2 | 2012 | 41 | 0.750 |
Why?
|
| Atherosclerosis | 4 | 2025 | 1007 | 0.750 |
Why?
|
| Biomarkers | 13 | 2024 | 3404 | 0.750 |
Why?
|
| Energy Metabolism | 2 | 2024 | 785 | 0.740 |
Why?
|
| Cardiovascular Diseases | 9 | 2020 | 2091 | 0.740 |
Why?
|
| Vitamin D | 3 | 2019 | 183 | 0.730 |
Why?
|
| Vitamin D Deficiency | 3 | 2019 | 74 | 0.730 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 139 | 0.720 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 210 | 0.690 |
Why?
|
| Albuminuria | 2 | 2023 | 112 | 0.640 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 419 | 0.640 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 13 | 0.630 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 3760 | 0.630 |
Why?
|
| Liraglutide | 1 | 2019 | 15 | 0.620 |
Why?
|
| Models, Biological | 1 | 2024 | 1443 | 0.620 |
Why?
|
| Drug Approval | 1 | 2019 | 47 | 0.610 |
Why?
|
| Registries | 7 | 2020 | 1579 | 0.600 |
Why?
|
| Kidney Diseases | 1 | 2023 | 489 | 0.580 |
Why?
|
| Abdominal Fat | 8 | 2012 | 24 | 0.560 |
Why?
|
| Young Adult | 24 | 2024 | 9952 | 0.530 |
Why?
|
| Health Status Disparities | 2 | 2016 | 253 | 0.520 |
Why?
|
| Adiponectin | 8 | 2019 | 128 | 0.510 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2018 | 75 | 0.510 |
Why?
|
| Endothelium | 1 | 2016 | 64 | 0.500 |
Why?
|
| Sleep | 4 | 2024 | 374 | 0.490 |
Why?
|
| Pericardium | 1 | 2016 | 92 | 0.490 |
Why?
|
| Risk Factors | 24 | 2024 | 10933 | 0.480 |
Why?
|
| Pulse Wave Analysis | 6 | 2023 | 52 | 0.470 |
Why?
|
| Heart Ventricles | 3 | 2018 | 784 | 0.460 |
Why?
|
| Peptide Hormones | 2 | 2006 | 71 | 0.450 |
Why?
|
| Hyperinsulinism | 4 | 2013 | 62 | 0.450 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2015 | 50 | 0.440 |
Why?
|
| Incretins | 4 | 2019 | 25 | 0.410 |
Why?
|
| Fetal Development | 1 | 2015 | 131 | 0.410 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 547 | 0.410 |
Why?
|
| Creatinine | 1 | 2015 | 412 | 0.410 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2005 | 294 | 0.410 |
Why?
|
| Calcinosis | 1 | 2014 | 191 | 0.390 |
Why?
|
| Puberty | 2 | 2024 | 104 | 0.380 |
Why?
|
| Body Weight | 4 | 2016 | 994 | 0.370 |
Why?
|
| Autoantibodies | 6 | 2021 | 456 | 0.370 |
Why?
|
| Resistance Training | 1 | 2012 | 32 | 0.370 |
Why?
|
| Absorptiometry, Photon | 7 | 2022 | 203 | 0.370 |
Why?
|
| Exercise | 2 | 2020 | 858 | 0.350 |
Why?
|
| Cohort Studies | 10 | 2024 | 5163 | 0.350 |
Why?
|
| Fasting | 8 | 2025 | 302 | 0.340 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 240 | 0.340 |
Why?
|
| Amino Acids | 3 | 2024 | 626 | 0.330 |
Why?
|
| Triglycerides | 4 | 2023 | 617 | 0.330 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2021 | 116 | 0.320 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 71 | 0.320 |
Why?
|
| Diabetic Neuropathies | 1 | 2020 | 56 | 0.310 |
Why?
|
| Lipolysis | 2 | 2021 | 75 | 0.300 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 381 | 0.300 |
Why?
|
| Adult | 18 | 2024 | 31536 | 0.280 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1499 | 0.270 |
Why?
|
| Thiazoles | 2 | 2016 | 100 | 0.270 |
Why?
|
| Coronary Artery Disease | 1 | 2014 | 892 | 0.270 |
Why?
|
| Amino Acids, Branched-Chain | 2 | 2025 | 75 | 0.260 |
Why?
|
| Peptide YY | 1 | 2006 | 19 | 0.250 |
Why?
|
| Dyslipidemias | 5 | 2021 | 241 | 0.250 |
Why?
|
| Lipoproteins | 2 | 2025 | 186 | 0.230 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2016 | 80 | 0.230 |
Why?
|
| Heart Rate | 3 | 2023 | 584 | 0.230 |
Why?
|
| Intra-Abdominal Fat | 2 | 2021 | 61 | 0.230 |
Why?
|
| Liver | 1 | 2012 | 1796 | 0.220 |
Why?
|
| Fluoxetine | 1 | 2024 | 44 | 0.220 |
Why?
|
| Prognosis | 4 | 2023 | 5007 | 0.220 |
Why?
|
| Diabetes Complications | 3 | 2024 | 207 | 0.220 |
Why?
|
| Prehypertension | 2 | 2016 | 11 | 0.220 |
Why?
|
| Sertraline | 1 | 2024 | 45 | 0.220 |
Why?
|
| Circadian Rhythm | 2 | 2024 | 317 | 0.220 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 75 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2023 | 6569 | 0.210 |
Why?
|
| Body Height | 1 | 2024 | 204 | 0.210 |
Why?
|
| Child, Preschool | 4 | 2024 | 14732 | 0.200 |
Why?
|
| Alanine Transaminase | 1 | 2023 | 162 | 0.200 |
Why?
|
| Glutamic Acid | 1 | 2024 | 209 | 0.200 |
Why?
|
| Gene-Environment Interaction | 1 | 2023 | 129 | 0.200 |
Why?
|
| Prevalence | 8 | 2020 | 2658 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 323 | 0.190 |
Why?
|
| Glutamine | 1 | 2024 | 211 | 0.190 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2020 | 74 | 0.190 |
Why?
|
| Melatonin | 1 | 2022 | 30 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2006 | 795 | 0.190 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 2 | 2023 | 573 | 0.180 |
Why?
|
| United States | 10 | 2020 | 11648 | 0.180 |
Why?
|
| Pennsylvania | 4 | 2017 | 61 | 0.180 |
Why?
|
| Pasteurella Infections | 1 | 2001 | 7 | 0.180 |
Why?
|
| Pasteurella multocida | 1 | 2001 | 7 | 0.180 |
Why?
|
| Treatment Failure | 2 | 2019 | 365 | 0.170 |
Why?
|
| Self Report | 1 | 2024 | 549 | 0.170 |
Why?
|
| Muscular Dystrophies | 1 | 2001 | 54 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 767 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 107 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 664 | 0.170 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 40 | 0.170 |
Why?
|
| Hypoglycemia | 3 | 2018 | 183 | 0.170 |
Why?
|
| Diastole | 2 | 2022 | 181 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 465 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 2020 | 115 | 0.160 |
Why?
|
| Energy Intake | 1 | 2023 | 493 | 0.160 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 436 | 0.160 |
Why?
|
| Bone Density | 1 | 2022 | 367 | 0.160 |
Why?
|
| Weight Loss | 1 | 2023 | 515 | 0.160 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2019 | 5 | 0.160 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2019 | 43 | 0.160 |
Why?
|
| Hyperemia | 1 | 2019 | 35 | 0.150 |
Why?
|
| Minority Groups | 2 | 2018 | 249 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 233 | 0.150 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 3 | 0.150 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 314 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 160 | 0.150 |
Why?
|
| Proteins | 1 | 2004 | 1035 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 281 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 5408 | 0.140 |
Why?
|
| Risk | 2 | 2017 | 761 | 0.140 |
Why?
|
| Viscera | 3 | 2008 | 55 | 0.140 |
Why?
|
| Pneumonia | 1 | 2001 | 334 | 0.130 |
Why?
|
| Texas | 2 | 2016 | 3627 | 0.130 |
Why?
|
| Age of Onset | 4 | 2020 | 622 | 0.130 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Calcifediol | 1 | 2016 | 15 | 0.130 |
Why?
|
| Reference Values | 3 | 2008 | 704 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1829 | 0.120 |
Why?
|
| Systole | 1 | 2016 | 206 | 0.120 |
Why?
|
| Hypertension | 3 | 2021 | 1396 | 0.120 |
Why?
|
| Pregnancy in Diabetics | 1 | 2015 | 17 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 481 | 0.120 |
Why?
|
| Ghrelin | 2 | 2006 | 56 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3409 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 2001 | 981 | 0.110 |
Why?
|
| Albumins | 1 | 2015 | 95 | 0.110 |
Why?
|
| Blood Pressure | 5 | 2011 | 1400 | 0.110 |
Why?
|
| Seasons | 1 | 2016 | 327 | 0.110 |
Why?
|
| Patient Selection | 1 | 2018 | 733 | 0.110 |
Why?
|
| Mass Screening | 2 | 2018 | 828 | 0.110 |
Why?
|
| Lipids | 1 | 2018 | 561 | 0.110 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 19 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1161 | 0.100 |
Why?
|
| Pregnancy | 3 | 2015 | 7543 | 0.100 |
Why?
|
| Islets of Langerhans | 2 | 2021 | 163 | 0.100 |
Why?
|
| Meals | 1 | 2013 | 60 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 63 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 635 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2012 | 52 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2019 | 12991 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1233 | 0.090 |
Why?
|
| Life Style | 3 | 2016 | 453 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2016 | 280 | 0.090 |
Why?
|
| Heart Atria | 1 | 2014 | 340 | 0.090 |
Why?
|
| Random Allocation | 1 | 2012 | 430 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 1178 | 0.080 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 171 | 0.080 |
Why?
|
| Child Behavior | 1 | 2012 | 236 | 0.080 |
Why?
|
| Fatty Liver | 1 | 2012 | 211 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1293 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1248 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2012 | 356 | 0.080 |
Why?
|
| Lipoproteins, HDL | 2 | 2006 | 117 | 0.080 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2008 | 24 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2011 | 2166 | 0.070 |
Why?
|
| Abdomen | 1 | 2008 | 135 | 0.070 |
Why?
|
| Comorbidity | 3 | 2018 | 1605 | 0.070 |
Why?
|
| Testosterone | 1 | 2013 | 611 | 0.070 |
Why?
|
| Disease Progression | 3 | 2018 | 2221 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 39 | 0.060 |
Why?
|
| Depression | 1 | 2015 | 1339 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 27 | 0.060 |
Why?
|
| Time Factors | 3 | 2024 | 6440 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2006 | 91 | 0.060 |
Why?
|
| Estradiol | 1 | 2008 | 486 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 59 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 1034 | 0.060 |
Why?
|
| Leptin | 2 | 2023 | 219 | 0.060 |
Why?
|
| Anthropometry | 1 | 2016 | 194 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2025 | 131 | 0.060 |
Why?
|
| Phenotype | 3 | 2023 | 4526 | 0.060 |
Why?
|
| ROC Curve | 3 | 2015 | 600 | 0.050 |
Why?
|
| Pediatrics | 2 | 2018 | 1211 | 0.050 |
Why?
|
| Sample Size | 1 | 2023 | 88 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 923 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 2850 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 123 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 230 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 3087 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 48 | 0.050 |
Why?
|
| Light | 1 | 2022 | 183 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2021 | 25 | 0.040 |
Why?
|
| Ear | 1 | 2001 | 27 | 0.040 |
Why?
|
| Hair | 1 | 2001 | 28 | 0.040 |
Why?
|
| Mouth Abnormalities | 1 | 2001 | 15 | 0.040 |
Why?
|
| Aging, Premature | 1 | 2001 | 28 | 0.040 |
Why?
|
| Toes | 1 | 2001 | 27 | 0.040 |
Why?
|
| Animals, Domestic | 1 | 2001 | 33 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2023 | 491 | 0.040 |
Why?
|
| Fingers | 1 | 2001 | 66 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 3011 | 0.040 |
Why?
|
| Life History Traits | 1 | 2020 | 6 | 0.040 |
Why?
|
| Micrognathism | 1 | 2001 | 67 | 0.040 |
Why?
|
| Behavioral Medicine | 1 | 2020 | 11 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1672 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3829 | 0.040 |
Why?
|
| Nose | 1 | 2001 | 102 | 0.040 |
Why?
|
| Saliva | 1 | 2001 | 134 | 0.040 |
Why?
|
| Echocardiography | 2 | 2018 | 1128 | 0.040 |
Why?
|
| Dogs | 1 | 2001 | 652 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 115 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 147 | 0.040 |
Why?
|
| Cleft Palate | 1 | 2001 | 154 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 2019 | 49 | 0.040 |
Why?
|
| Middle Aged | 3 | 2020 | 28943 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2437 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2021 | 17374 | 0.040 |
Why?
|
| Syndrome | 1 | 2001 | 1174 | 0.040 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2018 | 20 | 0.040 |
Why?
|
| Adolescent Medicine | 1 | 2018 | 22 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2018 | 41 | 0.030 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 36 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 168 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2018 | 81 | 0.030 |
Why?
|
| Health Promotion | 1 | 2020 | 399 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 133 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 34781 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 256 | 0.030 |
Why?
|
| Gynecology | 1 | 2018 | 129 | 0.030 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2016 | 19 | 0.030 |
Why?
|
| Glucagon | 1 | 2016 | 151 | 0.030 |
Why?
|
| Inflammation | 2 | 2018 | 1519 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2018 | 166 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2018 | 182 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 20 | 0.030 |
Why?
|
| Endocrinology | 1 | 2018 | 128 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8542 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 59 | 0.030 |
Why?
|
| Medical Records | 1 | 2016 | 189 | 0.030 |
Why?
|
| Stillbirth | 1 | 2015 | 103 | 0.030 |
Why?
|
| Heart | 1 | 2019 | 689 | 0.030 |
Why?
|
| E-Selectin | 1 | 2014 | 38 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 902 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 65 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 122 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 606 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 333 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 742 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 2014 | 26 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2912 | 0.030 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 31 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 294 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 113 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2015 | 264 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 238 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2015 | 359 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 669 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 473 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 2186 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2024 | 4703 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 357 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1656 | 0.020 |
Why?
|
| Carnitine | 1 | 2012 | 69 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 743 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 713 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2009 | 20 | 0.020 |
Why?
|
| Immunoassay | 1 | 2009 | 135 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 2554 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 351 | 0.020 |
Why?
|
| Body Size | 1 | 2007 | 68 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 777 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2311 | 0.020 |
Why?
|
| Proinsulin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2006 | 49 | 0.020 |
Why?
|
| Infant | 1 | 2001 | 13047 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 305 | 0.010 |
Why?
|
| Exercise Test | 1 | 2006 | 258 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 547 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1949 | 0.010 |
Why?
|
| Family | 1 | 2005 | 595 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2140 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1125 | 0.010 |
Why?
|